Immunocore director granted 27,492 stock options

Immunocore Holdings plc director Peter John Ratcliffe received a new stock option grant.

Rhea-AI Filing Summary

Immunocore Holdings plc director Peter John Ratcliffe received a new stock option grant. On May 27, 2026, he was granted options over 27,492 ordinary shares at an exercise price of $28.52 per share, with no cash paid for the grant itself.

The options expire on May 26, 2036 and represent his entire reported option position of 27,492 options following this transaction. According to the terms, the award will vest at the earlier of May 27, 2027 or the day immediately prior to Immunocore’s next annual general meeting, provided he continues in service through the vesting date.

Insider Trade Summary

Grant/Award: 27,492 shares

Grant/Award 1 txn

Insider Ratcliffe Peter John

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	27,492	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 27,492 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Options granted: 27,492 options Exercise price: $28.52/share Expiration date: May 26, 2036 +2 more

5 metrics

Options granted 27,492 options Grant of share options on May 27, 2026

Exercise price $28.52/share Exercise price for the 27,492 options

Expiration date May 26, 2036 Option award expiration

Post-transaction options held 27,492 options Total options owned following the grant

Vesting latest date May 27, 2027 Latest vesting date, subject to earlier AGM-related vesting

Key Terms

Share Option (Right to Buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more

5 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "28.5200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-05-26T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The shares subject to the option award shall vest at the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunocore (IMCR) director Peter John Ratcliffe receive in this Form 4?

Peter John Ratcliffe received a grant of stock options over 27,492 Immunocore ordinary shares. The options are a compensation-related award, not an open-market share purchase, and give him the right to buy shares at a fixed exercise price of $28.52.

What are the key terms of Peter John Ratcliffe’s new Immunocore stock options?

The new award covers 27,492 options with an exercise price of $28.52 per share and an expiration date of May 26, 2036. These options were granted at no upfront cost as part of his role with Immunocore Holdings plc.

When do Peter John Ratcliffe’s Immunocore options vest according to this filing?

The options vest at the earlier of May 27, 2027 or the day immediately before Immunocore’s next annual general meeting. Vesting is conditional on Ratcliffe’s continuous service with the company through the applicable vesting date, as described in the award footnote.

How many Immunocore options does Peter John Ratcliffe hold after this Form 4 transaction?

After this transaction, Ratcliffe holds 27,492 stock options in Immunocore. This total equals the full size of the new grant, indicating the filing reports his current option position related to this award following the grant on May 27, 2026.

Does this Immunocore Form 4 show Peter John Ratcliffe buying or selling shares in the market?

The Form 4 reports a grant of stock options, not an open-market buy or sell of Immunocore shares. It records a compensation award giving Ratcliffe the right to purchase 27,492 ordinary shares at a set exercise price in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 07:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ratcliffe Peter John

(Last) (First) (Middle)

C/O IMMUNOCORE HOLDINGS PLC

92 PARK DRIVE, MILTON PARK

(Street)

ABINGDON OXFORDSHIRE OX14 4RY

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunocore Holdings plc [ IMCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$28.52	05/27/2026		A		27,492		(1)	05/26/2036	Ordinary Shares	27,492	$0	27,492	D

Explanation of Responses:

1. The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Lily Hepworth, Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)